2,3,4′,5-tetrahydroxystilbene-2-O-β-D-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 3, 2008, Pages 310-316

  Zhang, Wei ^b   Wang, Chun Hua ^b   Li, Feng ^b   Zhu, Wei Zhong ^a,b  

^a NANTONG UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

Author keywords

2,3,4 ,5 tetrahydroxystilbene 2 O D glucoside; Atherosclerosis; C reactive protein; Interleukin 6; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Rat; Tumour necrosis factor

Indexed keywords

2,3,4',5 TETRAHYDROXYSTILBENE 2 O BETA DEXTRO GLUCOSIDE; C REACTIVE PROTEIN; EOSIN; GELATINASE A; GELATINASE B; GLUCOSIDE; HEMATOXYLIN; INTERLEUKIN 6; LIPID; MATRIX METALLOPROTEINASE; MESSENGER RNA; SIMVASTATIN; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; ATHEROSCLEROSIS; CONTROL GROUP; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID BLOOD LEVEL; LIPID DIET; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSIDES; INFLAMMATION; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; STILBENES;

EID: 39149083101     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04824.x     Document Type: Article

References (42)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993 362 : 801 10.
2. Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fujikawa H, Shimada K. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 2002 161 : 185 92.
3. Davies MJ. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation 1998 97 : 2382 3.
4. Galis ZS, Sukhova GK, Larck MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994 94 : 2493 503.
5. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ. Res. 2003 92 : 827 39.
6. Pasterkamp G, Schoneveld AH, Hijnen DJ et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000 150 : 245 53.
7. Barbosa FJ, Gerlach RF, Tanus-Santos JE. Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations. Basic Clin. Pharmacol. Toxicol. 2006 98 : 559 64.
8. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003 107 : 1579 85.
9. Altieri P, Brunelli C, Garibaldi S et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur. J. Clin. Invest. 2003 33 : 648 56.
10. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
11. Koenig W, Sund M, Frohlich M et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984-92. Circulation 1999 99 : 237 42.
12. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998 98 : 731 3.
13. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ. Res. 2001 89 : 763 11.
14. Kereiakes DJ. Inflammation as a therapeutic target: A unique role for bciximab. Am. Heart. J. 2003 146 (Suppl S1 4.
15. Ikeda U, Ikeda M, Oohara T et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am. J. Physiol. 1991 260 : H1713 17.
16. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998 394 : 894 7.
17. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000 101 : 1767 72.
18. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991 89 : 247 54.
19. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000 101 : 2049 53.
20. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 2137 8.
21. Ohta H, Wada H, Niwa T et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005 180 : 11 17.
22. Shan LM, Zhao YL, Zhang JC. The molecular mechanism of anti-atherosclerosis by the new combination of PPVP in atherosclerotic rats. Chin. Pharmacol. Bull. 2004 20 : 255 8 (in Chinese with an English abstract).
23. Oyang JP, Wang BH, Liu YM. The effects and the mechanism of atherogenesis by sodium ferulate in hyperlipemia rabbits. Chin. Pharmacol. Bull. 2002 18 : 207 10 (in Chinese with an English abstract).
24. Jain MK, Ridker PM. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 2005 4 : 977 87.
25. Frostegård J, Ulfgren A, Nyberg P. Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999 145 : 33 43.
26. Wassmann S, Laufs U, Muller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 300 5.
27. Hanefeld M, Marx N, Pfutzner A et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J. Am. Coll. Cardiol. 2007 49 : 290 7.
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
29. Fukumoto Y, Libby P, Rabkin E et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 2001 103 : 993 9.
30. Jackson C, Nguyen M, Arkell J, Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis: Targetting gelatinase A activation. Inflamm. Res. 2001 50 : 183 6.
31. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs). The beginning of phase I or the termiantion of phase II clinical trials. Cancer Metastasis Rev. 2003 22 : 177 91.
32. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metallproteinases. Mol. Cell. Biochem. 2003 252 : 305 29.
33. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc. Med. 2002 12 : 97 101.
34. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ. Res. 2001 89 : 201 10.
35. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin. Invest. Drugs 2000 9 : 993 1007.
36. Lee B, Moon SK. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscle cells. J. Nutr. 2005 135 : 2767 73.
37. Abe N, Osanai T, Fujiwara T, Kameda K, Matsunaga T, Okumura K. C-Reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages. Inhibitory effect of fluvastatin. Life Sci. 2006 78 : 1021 8.
38. Eckart RE, Uyehara CF, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J. Interv. Cardiol. 2004 17 : 27 31.
39. Hattori R, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: Role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 2002 282 : H1988 95.
40. Das S, Falchi M, Bertelli A, Maulik N, Das DK. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung 2006 56 : 700 6.
41. Barthomeuf C, Lamy S, Blanchette M, Boivin D, Gingras D, Beliveau R. Inhibition of sphingosine-1-phosphate- and vascular endothelial growth factor-induced endothelial cell chemotaxis by red grape skin polyphenols correlates with a decrease in early platelet-activating factor synthesis. Free Radic. Biol. Med. 2006 40 : 581 90.
42. Ungvari ZI, Orosz Z, Rivera A et al. Resveratrol increases vascular oxidative stress resistance. Am. J. Physiol. Heart Circ. Physiol. 2007 292 : H2417 24.